Alcobra, an Israeli biopharmaceutical company focused on the development of a drug to treat ADHD, announced terms for its IPO on Tuesday. The Tel Aviv, Israel-based company plans to raise $15 million by offering 1.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Alcobra would command a fully diluted market value of $102 million. Alcobra, which was founded in 2008 and is yet to generate any revenue, plans to list on the NASDAQ under the symbol ADHD. . Aegis Capital is the sole underwriter on the deal.
